RxDoctor Payments Data

Peter Weissman

Miami, FLNPI 1841274529

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $83,050 of the $99,285 with a category attached, or 83.6%. Radius Health, Inc. accounts for 64.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $79,950 and has fallen 99.9% since, to $92 in 2022.

$99,285in general payments, 2019–2025

Across 165 payments — averaging $601.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$64K
  • Amgen$31K
  • GSK$3K
  • AstraZeneca$197
  • Abbott$89
  • Medtronic$72
  • plus $338 from 9 others
$302,559in research payments, 2019–2025

Across 137 payments — averaging $2208.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$122K
  • Bayer$82K
  • Radius Health, Inc.$62K
  • Takeda Pharmaceuticals U.S.A., Inc.$19K
  • GSK$19K

What the payments were for

  • Consulting fees$3,2203%
  • Speaking & faculty fees$83,05084%
  • Travel & lodging$10,21110%
  • Food & beverage$2,7543%
  • Education$500%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →